Purpose/Goals The aims of this study were to (1) Identify the predictors of symptoms of anxiety Tie2 IL1A kinase inhibitor and (2) Evaluate the differential association of somatic and non-somatic symptoms of depression on anxiety over time in persons with multiple sclerosis (MS). MS (57%). After adjusting for demographic and disease related variables anxiety (<.001) employment (=.07) and non-somatic depressive symptoms (=.10) at baseline significantly predicted anxiety at time 2 depression and anxiety may be influenced by age (Janssens et al. 2006 Jones et al. 2012 Mattioli Bellomi Stampatori Parrinello & Capra 2011 Williams et al. 2005 Wood et al. 2013 Tie2 kinase inhibitor time since onset (Chwastiak et al. 2002 Forman & Lincoln 2010 Janssens et al. 2006 Korostil & Feinstein 2007 Williams et al. 2005 and disability (Beiske et al. 2008 Mattioli et al. 2011 Moore et al. 2012 we explored the potential synergistic (i.e. interaction) effect between depression and age time since onset and disability on anxiety over time to determine if a differential pattern of association would emerge between these factors. Methods Recruitment and Methods Participants were people enrolled in a big study examining the knowledge of coping with MS who finished some self-report questionnaires (referred to below). The info for today's evaluation represent two period points 4 aside. Detailed info on recruitment can be reported somewhere else (Amtmann et al. 2012 Tie2 kinase inhibitor Quickly participants had been recruited from the higher Northwest chapter from the Country wide Multiple Sclerosis Culture. From the 1 628 who have been mailed invites 1 367 fulfilled eligibility requirements (age group 18 years or old with self-reported MS) and had been mailed a paper study or a link to the online survey. Of the 1 270 individuals who completed Tie2 kinase inhibitor this baseline assessment 562 randomly selected participants were invited to continue participating in the survey. A total of 513 individuals (93% response rate) completed the four-month follow-up survey either online (n=119) or on paper (n=394). All participants provided informed consent and received $25 per completed survey. Procedures were approved by the Human Subjects Division of the primary research institution. Measures Demographics Participants provided demographic and basic medical information including age sex race/ethnicity education employment and time since onset of MS. Disability Status Participants completed the self-reported Expanded Disability Status Scale Mobility (EDSS-Mobility; (Bowen Gibbons Gianas & Kraft 2001 A continuous score (range 1-9) was used for all analyses. For descriptive purposes participants Tie2 kinase inhibitor were divided into three categories: no mobility aid (≤ 4 minimal severity) bilateral or unilateral mobility aid (4.5-6.5 intermediate severity) and use of a wheelchair for mobility (≥ 7 advanced severity). Pain The Numeric Rating Scale (NRS) assessed pain severity with participants rating the intensity of their pain over the past week from 0 (no pain) to 10 (highest pain imaginable). This single item NRS is widely utilized and is well validated (Jensen & Karoly 2011 Fatigue The Fatigue Severity Scale (FSS) was utilized to measure the severity and impact of fatigue. The FSS includes nine items ranging from 1 (no symptoms) to 7 (severe fatigue) Tie2 kinase inhibitor with higher scores indicating greater levels of fatigue. The FSS has high sensitivity and good internal consistency (Cronbach’s α = .88; Krupp LaRocca Muir-Nash & Steinberg 1989 Anxiety The Hospital Anxiety and Depression Scale-Anxiety (HADS-A) is a 7-item measure of anxiety symptom severity. Items are rated on a 4-point Likert scale with higher scores indicating greater anxiety symptoms (Zigmond & Snaith 1983 The HADS-A has been validated for use in identifying anxiety in individuals with MS (Honarmand & Feinstein 2009 Depression The Patient Health Questionnaire – 9-item (PHQ-9) is a measure of depression symptom severity developed in parallel using the analysis of Main Depressive Disorder in the DSM-IV (Spitzer Kroenke & Williams 1999 Products are rated relating to how continual the symptom has been around the past fourteen days: 0 (never) 1 (many times) 2 (over fifty percent the times) or 3 (just about any day time). The PHQ-9 shows good internal uniformity (Cronbach’s α = .89) and test-retest.